MedPath

Study Evaluating Effexor XR in Elderly Patients With Major Depression.

Phase 3
Completed
Conditions
Depression
Registration Number
NCT00225485
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

Phase III study evaluating Effexor XR in elderly patients with major depression.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients diagnosed with major depression based on DSM-IV-TR
  • Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" of HAM-D at baseline
Exclusion Criteria
  • Patients with schizophrenia or any other psychotic disorder
  • Patients with history or presence of bipolar disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy
Secondary Outcome Measures
NameTimeMethod
Difference of total score of HAM-D17 between baseline and final-on-therapy
Remission rate of HAM-D17 at the final-on-therapy
© Copyright 2025. All Rights Reserved by MedPath